Shandong Buchang Pharmaceuticals' (SHA:603858) unit, Baoding Tianhao Pharmaceutical, received the drug registration certificate for oseltamivir phosphate dry suspension from the Chinese drug administration, according to a Shanghai Stock Exchange disclosure on Friday.
The certificate will allow the manufacturing and sales of the drug, which is used for the treatment of patients with influenza A and B.
The pharmaceutical company invested 14.4 million yuan into the research and development of the drug.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.